Sugi Predict

Sugi Predict / Compounds / SCHEMBL2333731

SCHEMBL2333731

SCHEMBL2333731

CCOC(=O)[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H]1N

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.44
▸ MEN1 O00255 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ PDE4B Q07343 1/20 0.39
▸ DPP4 P27487 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2333732 1.00 NR1H2 (0.44) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL15198324 1.00 NR1H2 (0.44) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL2515174 1.00 NR1H2 (0.44) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL4099420 1.00 NR1H2 (0.44) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL2930651 0.90 NR1H2 (0.50) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL2930654 0.90 NR1H2 (0.50) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL1052491 0.90 NR1H2 (0.50) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL1220866 0.88 ALDH1A1 (0.45) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL1219339 0.88 ALDH1A1 (0.45) NR1H2MEN1ALDH1A1KMT2ATSHR
SCHEMBL21682484 0.88 ALDH1A1 (0.45) NR1H2MEN1ALDH1A1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO disclosed
EP-4688792-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 — — EP disclosed
US-20240368193-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-11-07 — — US disclosed
WO-2024206766-A1 KRAS INHIBITORS ELI LILLY AND COMPANY (US) 2024-10-03 — — WO disclosed
EP-3833672-B1 TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE SRL (IT) 2024-09-18 — — EP disclosed
US-20240156780-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AXIAL THERAPEUTICS, INC. (US) 2024-05-16 — — US disclosed
WO-2024091511-A1 HETEROCYCLIC TEAD INHIBITORS LIGHT HORSE THERAPEUTICS, INC. (US) 2024-05-02 — — WO disclosed
US-20240116926-A1 HETEROAROMATIC COMPOUNDS ASTRAZENECA AB (SE) 2024-04-11 — — US disclosed
US-11951094-B2 TLR2 modulator compounds, pharmaceutical compositions and uses thereof AXIAL THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
WO-2023209086-A1 BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER ASTRAZENECA AB (SE) 2023-11-02 — — WO disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 — — US disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 — — US disclosed
US-20090325948-A1 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE HURLEY TIMOTHY BRIAN 2009-12-31 — — US disclosed
CN-101495186-A Inhibitors of undecaprenyl pyrophosphate synthase NOVARTIS AG (CH) 2009-07-29 — — CN disclosed
EP-2059305-A2 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE Novartis Ag (CH) 2009-05-20 — — EP disclosed
WO-2009053694-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-30 — — WO disclosed
WO-2008014307-A2 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2008-01-31 — — WO disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 — — EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 — — WO disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325948-A1 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE FDPS, UMPS, GGPS1 NR1H2 1323/4885MEN1 2345/4885ALDH1A1 3119/4885
US-20240116926-A1 HETEROAROMATIC COMPOUNDS CYP1B1, CYP2D6, CYP1A1 NR1H2 510/4885MEN1 572/4885ALDH1A1 130/4885
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD NR1H2 2641/4885MEN1 1437/4885ALDH1A1 494/4885
US-20240156780-A1 TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF TLR2, TLR3, TLR4 NR1H2 157/4885MEN1 4682/4885ALDH1A1 4063/4885
US-11951094-B2 TLR2 modulator compounds, pharmaceutical compositions and uses thereof TLR2, TLR3, TLR4 NR1H2 157/4885MEN1 4682/4885ALDH1A1 4063/4885
US-20240368193-A1 KRAS INHIBITORS KRAS, NRAS, HRAS NR1H2 1327/4885MEN1 270/4885ALDH1A1 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.